Loading stock data…
Immatics N.V. (IMTX)
$9.56+0.04 (+0.42%)
After Hours$9.56+0.00 (+0.00%)· Last close Jun 29
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immatics N.V. in the Healthcare sector is trading at $9.56 with a market capitalization of $1.4B. Wall Street consensus targets $18.77 (8 analysts), implying a +96.4% move over the next 12 months. The stock is currently 23% below its 52-week high of $12.41, remaining 3.6% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +96.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $7.61M↓ | $19.76M↑ | $5.19M↑ | $4.74M↓ | $18.58M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$66.06M↓ | -$38.88M↑ | -$54.63M↓ | -$53.13M↓ | -$35.37M |
| Net Income | -$57.81M↓ | -$35.70M↑ | -$50.55M↑ | -$70.35M↓ | -$39.85M |
Peer Comparison
JNJUNHPFE
Fundamentals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies wi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.04%
Volume
Today's trading volume
283,206
Recent News
Analysts Are Updating Their Immatics N.V. (NASDAQ:IMTX) Estimates After Its First-Quarter Results
It's shaping up to be a tough period for Immatics N.V. ( NASDAQ:IMTX ), which a week ago released some disappointing...
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
ACAD Q1 Earnings & Revenues Miss Estimates Despite Y/Y Sales Growth
Acadia's first-quarter earnings and revenues miss estimates despite 10% sales growth, driven by Nuplazid and Daybue demand.
Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock up on better-than-expected first-quarter results on account of robust Rezdiffra sales, driven by strong MASH demand and rising patient adoption.
RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals reports a narrower-than-expected Q1 loss, but revenues fall sharply as Roche collaboration income declines year over year.